Treatment of central serous chorioretinopathy with topical NSAIDs

Sepehr Bahadorani, Kyle Maclean, Kendall Wannamaker, Edward Rickie Chu, Nathan Gresores, Jeong Hyeon Sohn, Roberto Diaz-Rohena, Michael A. Singer

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery. Methods: An IRB-approved retrospective review was conducted on patients that had been diagnosed with a new-onset, symptomatic case of CSCR. Patients were either observed only (13 untreated eyes) or treated with topical bromfenac or nepafenac (14 eyes) over an average of about a 4–5 week follow-up period. Results: There was no statistical significance between central macular thickness (CMT) and visual acuity of treatment and control groups at the initial presentation. However, at the follow-up visit, CMT reductions in the treatment group were significantly higher than in the control group (p<0.006). Conclusion: Use of topical NSAIDs in the treatment of acute CSCR leads to a faster rate of reduction in the subretinal fluid volume over a follow-up period of a few weeks.

Original languageEnglish (US)
Pages (from-to)1543-1548
Number of pages6
JournalClinical Ophthalmology
StatePublished - 2019


  • Bromfenac
  • CSC
  • CSCR
  • Central serous chorioretinopathy
  • NSAIDs
  • Nepafenac
  • SRF
  • Subretinal fluid

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Treatment of central serous chorioretinopathy with topical NSAIDs'. Together they form a unique fingerprint.

Cite this